Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

Azafaros believes its oral dual inhibitor approach could treat lysosomal storage disorders that affect the brain

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with neuropathological effects.

Seeded in July 2018 by founding investor BioGeneration Ventures

Read the full 455 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers